800-234-336
Kalkine 0
countryflagNZ

WBCPI 100.32 0.0% CBA 164.72 0.5801% BHP 38.06 0.9014% RIO 114.92 0.9576% CSL 241.89 0.8884% WBC 32.04 1.0726% NAB 35.11 0.6017% NEM 85.2 3.4608% WES 75.74 -0.0396% ANZ 28.84 1.5493% MQG 192.72 1.2291% GMG 28.74 0.8421% XYZ 88.34 -0.2484% RMD 36.08 8.5113% TLS 4.44 -0.4484% FMG 15.52 1.0417% TCL 13.89 0.072% ALL 64.25 0.0779% WOW 31.53 -0.3791% WDS 20.01 -2.0078%

Syntara Limited

Healthcare AU SNT

0.054AUD
0.003(5.88%)

Last update at 2025-04-24T06:10:00Z

Day Range

0.050.06
LowHigh

52 Week Range

0.010.10
LowHigh

Fundamentals

  • Previous Close 0.05
  • Market Cap87.71M
  • Volume2345294
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.77500M
  • Revenue TTM8.15M
  • Revenue Per Share TTM0.006
  • Gross Profit TTM -0.23000M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown
Breakdown
Breakdown

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SNT
Syntara Limited		 0.003 5.88% 0.05 - 20.45 10.75 4.48 6.32 -2.1607
AFP
AFT Pharmaceuticals Ltd		 - -% 2.34 23.40 11.38 1.31 3.13 1.53 13.22
LV1
Live Verdure Ltd		 0.01 3.06% 0.51 3.05 - 1.59 0.86 47.31 1.28
VLS
Vita Life Sciences Ltd		 0.04 2.04% 1.75 10.94 - 1.22 1.85 0.87 5.12
MVP
Medical Developments International		 - -% 0.46 - 166.67 1.35 0.93 1.42 278.77

Reports Covered

Stock Research & News

View All

Profile

Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company's lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson's disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Syntara Limited

20A Rodborough Road, Frenchs Forest, NSW, Australia, 2086

Key Executives

Name Title Year Born
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Secretary 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964
Ms. Kristen Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin Head of Medical & Regulatory Affairs - Alliance Management 1972
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Secretary 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Secretary 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.